EBS — Emergent BioSolutions Cashflow Statement
0.000.00%
Last trade - 00:00- $624.99m
- $1.04bn
- $1.04bn
- 67
- 63
- 100
- 91
Annual cashflow statement for Emergent BioSolutions, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 305 | 231 | -212 | -761 | -191 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 110 | 75.9 | 64.9 | 513 | 60.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 8.8 | -156 | -30.7 | -75.1 | 85.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 536 | 321 | -34.1 | -206 | 58.7 |
| Capital Expenditures | -151 | -225 | -360 | -57.9 | -22.9 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -21.8 | 270 | 148 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -151 | -225 | -381 | 212 | 125 |
| Financing Cash Flow Items | -25 | -15 | -5.9 | -2.5 | -15.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 69.5 | -141 | 481 | -536 | -190 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 454 | -45.2 | 66.3 | -531 | -6.1 |